385
Views
3
CrossRef citations to date
0
Altmetric
Editorials

A New Era in Anticancer Therapy/Imatinib—A New Era in Anticancer Therapy

, &
Pages 769-770 | Published online: 15 Apr 2014
 

ABSTRACT

Bulgarian Pharmaceutical Association has granted Imatinib 1st prize for prescription drugs in 2008. This review addresses the role of imatinib in anticancer therapy. Imatinib is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt.

ABSTRACT

Imatinib, a synthetic tyrosine kinase inhibitor, is the first member of a new class of agents. The introduction of imatinib has brought a new era in anticancer therapy that is designed to interfere with a specific molecular target, usually a protein with a critical role in tumor growth or progression. Imatinib serves as a model for the development of other tyrosine kinase inhibitors and for targeted therapy in general.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.